Virtu Financial LLC Lineage Cell Therapeutics, Inc. Transaction History

Virtu Financial LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.89 - $1.47 $69,824 - $115,327	78,454 New	78,454 $78,000
Q1 2023 May 01, 2023	SELL	$1.2 - $1.53 $32,305 - $41,189	-26,921 Reduced 60.58%	17,521 $26,000
Q4 2022 Feb 15, 2023	BUY	$1.02 - $1.5 $35,102 - $51,621	34,414 Added 343.18%	44,442 $52,000
Q3 2022 Nov 07, 2022	SELL	$1.13 - $1.77 $3,787 - $5,933	-3,352 Reduced 25.05%	10,028 $11,000
Q2 2022 Aug 09, 2022	BUY	$1.12 - $1.61 $14,985 - $21,541	13,380 New	13,380 $21,000
Q3 2021 Nov 12, 2021	SELL	$2.26 - $2.86 $122,336 - $154,814	-54,131 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$2.17 - $3.0 $117,464 - $162,393	54,131 New	54,131 $154,000
Q4 2020 Feb 24, 2021	SELL	$0.95 - $1.83 $38,302 - $73,781	-40,318 Closed	0 $0
Q3 2020 Dec 11, 2020	SELL	$0.75 - $1.09 $28,293 - $41,119	-37,724 Reduced 48.34%	40,318 $38,000
Q2 2020 Aug 07, 2020	BUY	$0.71 - $1.18 $55,409 - $92,089	78,042 New	78,042 $68,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.